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Introduction
Pancreatic cystic lesions (PCLs) comprise a diverse group of histopathologic bodies possessing varying degrees of malignancy. The majority of PCLs (80%-90%) are pseudocysts (PC), the remainder are mucinous neoplasms (MCNs, including mucinous cystadenomas (MCyA) and mucinous cystadenocarcinomas (MCyA-CA)), intraductal papillary mucinous year survival rate for patients with MCNs and IPMNs is nearly 100%. With the development of PCLs, save for SCyA, are recommended for resection due to their tendency to be malignant. However, a dilemma arises with patients at an increased risk for postsurgical complications.
critical information, EUS-FNA has recently attracted more attention, particularly to those interested in researching pancreatic cystic neoplasms.
The international consensus guidelines for management of IPMN and MCN have proposed to include examination by way of EUS-FNA [6] . However, as PCLs, as a category, contain more lesions of the PC and MCyA types than IPMN/MCN, misdiagnoses by various image modalities, including EUS-FNA, occur. As a result, despite published literature evaluating EUS-FNA on pancreatic mucinous neoplasm, and meta-analysis suggesting that analysis evaluating the use of EUS-FNA in detecting malignancy of PCLs.
Materials and Methods

Study selection and subgroup categories
Prior to conducting a literature search, we agreed to include only those studies that met all of the following criteria: (1) analyzed cytology from EUS-FNA on subjects for diagnosis of pancreatic cystic lesions (or separately reported PCLs from others); (2) published in English; (3) utilized, as a gold standard, surgical
We excluded studies that met any of the following criteria: (1) review articles, case reports, letters to the editor, brief communications, or rapid communications; (2) studies that used specimens from CT guided or abdominal ultrasound or from percutaneous puncture; (3) studies that used conclusions from articles reported PCLs as malignant, others reported cytology diagnoses as non-diagnostic, benign, atypical, suspicious, potential, or malignant. To avoid divergence of positive results and to reduce any atypical and suspicious cytology results as malignant results. The histopathological determination of including publication year, location, number of medical centers, patients and clinical experts, study design and time interval from EUS-FNA to pathological diagnosis, needle size, average number of needles for each case, successful aspiration rate, age, ratio of male: female patients, and the presence of an onsite cytopathologist. Subsequently, subgroup analysis was performed based on the obtained information. under the curve (AUC) close to 1 would indicate that EUS-FNA is a well-validated tool for diagnosis of PCLs. Next, meta regression analysis was performed to explore potential causes of heterogeneity according to the analysis of sensitivity were performed. Each of these described statistical procedures was performed using software version 11.0 (Stata Corporation, College Station, Texas). When a count of zero occurred in the
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Systematic review
among which, 126 were thoroughly reviewed. We retrieved 18 articles published between Table 2 . There were no reports of severe complications during any of the procedures in the included articles.
Quality of studies
Meta-analysis dysplasia and carcinoma in situ, or invasive carcinoma, as the determinant of a positive 2 > distribution pattern, suggested to us the presence of threshold effect. Further analysis that EUS-FNA has a great value for diagnosing malignant PCLs. practice, the majority of patients diagnosed with benign lesions such as simple cyst by other convenient inspection before, they do not carry out EUS-FNA and will not undergo surgical resection. Statistically, this have in some degree led to lower sensitivity falsely unavoidably. Thus, EUS-FNA reasonably deserves a higher sensitivity than we have, here, concluded.
analysis reveals gender as a factor that causes heterogeneity between studies, as those with more female than male patients have a lower sensitivity (38% vs. 62%). Studies grouped data is appropriate, but that improvement by meta-regression was not always statistically trials, these subgroup factors may, in fact, be critical.
Although several large sample studies reported primary complications of 1-3.6% [36] [37] [38] [39] for PCLs, higher than that of solid pancreatic lesions, none of included studies reported severe complications during EUS-FNA.
In order to interpret the results of this study, the following strengths and limitations must be considered : 1) each study has its own descriptions for malignancy, gold standard of diagnosis, study design, and localization of pancreas, allowing for divergence between the studies themselves; 2) some important factors (such as size of cyst) are not available in To date, most studies have focused on either pancreatic solid lesions or mucinous pancreatic neoplasm. There are a limited number of studies that focus primarily on pancreatic analysis that evaluated the diagnostic accuracy of EUS-FNA in differentiation of mucinous category of pancreatic cystic lesions and mostly develop into malignant bodies.
Advantages such as being minimally invasive, possessing higher accuracy than CT or may lead to increased use of EUS-FNA in diagnosis of cystic pancreatic lesions. In addition,
In order to further investigate the validity of cytology from EUS-FNA for the early diagnosis and prediction of prognosis in PCLs, future studies will consider additional practical factors. We hope that a more reasonable algorithm of EUS-FNA will be developed
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